CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymph...
Phase 3
Boston, Massachusetts, United States and 8 other locations
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 1
Boston, Massachusetts, United States and 3 other locations
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
Boston, Massachusetts, United States and 51 other locations
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
Boston, Massachusetts, United States and 173 other locations
in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia...
Phase 2
Boston, Massachusetts, United States and 8 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
Boston, Massachusetts, United States and 10 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
Boston, Massachusetts, United States and 56 other locations
Adult T-cell leukemia/lymphoma (ATLL) is a rare form of cancer found mostly among people from the Caribbean islands, Western Africa, Brazil,...
Phase 2
Boston, Massachusetts, United States and 3 other locations
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...
Phase 1, Phase 2
Boston, Massachusetts, United States and 7 other locations
therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia...
Phase 2
Boston, Massachusetts, United States and 3 other locations
Clinical trials
Research sites
Resources
Legal